Knight Therapeutics (GUD) M&A Announcement summary

Deal rationale and strategic fit

• Exclusive agreements signed to commercialize six products in Canada, including MYFEMBREE®, ORGOVYX®, vibegron, and three mature products, effective June 4, 2025, expanding the women's health and urology portfolio and enhancing access for patients and providers.

• Portfolio includes three mature products and three innovative assets (MYFEMBREE, ORGOVYX, Vibegron), synergistic with existing offerings.

• Transaction aligns with strategy to build a balanced portfolio of innovative and cash-generating assets, enhancing Canadian business scale.

• Recent deals, including this one, will add over 50 products to the Canadian portfolio, positioning Canada as a top contributor alongside Brazil.

• The transaction aligns with Sumitomo's strategy to focus on core U.S. brands and accelerate its oncology, regenerative medicine, and cell therapy pipeline.

Financial terms and conditions

• Total consideration: CAD 25.4 million upfront plus up to CAD 15.75 million in contingent milestone payments.

• Estimated CAD 7 million investment in inventory over the next eight months.

• Portfolio generated CAD 11.2 million in revenues for the 12 months ending March 31, 2025.

• Milestone payments are staggered and tied to sales targets, not a single lump sum.

Synergies and expected cost savings

• No infrastructure acquired; minimal headcount increase expected (4–6 people across sales, medical, marketing).

• Mature assets provide cash flow to fund investment in growth products.